Laurent Machet

Prof. Laurent Machet

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2007 in Archives of Dermatology
Verified
Journal Article
Open access
PDF file
FGFlorent Grange
Florent Grange
Marie BEYLOT-BARRYMarie BEYLOT-BARRY
Marie BEYLOT-BARRY
PCPhillipe Courville
Phillipe Courville
EMEve Maubec
Eve Maubec
MBMartine Bagot
Martine Bagot
TPTony Petrella
Tony Petrella
In 2005, a new World Health Organization–European Organization for Research and Treatment of Cancer (WHO-EORTC) classification of cutaneous lymphomas was proposed1 and was widely accepted2,3 as an important consensual advance for the characterization and management of cutaneous lymphomas. In this classification, primary cutaneous B-cell lymphomas (PCBCLs) were divided into the following 3 main groups: primary cutaneous marginal zone B-cell lymphoma, primary cutaneous follicle center cell lymphoma, and primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL LT). Whereas the first 2 groups had been identified long before and studied in numerous large reports,4-10 the third group was newly defined and had not yet been characterized by large multicenter studies.

12 July 2011 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
TJT. Jouary
T. Jouary
CLC. Leyral
C. Leyral
BDB. Dreno
B. Dreno
ADA. Doussau
A. Doussau
BSB. Sassolas
B. Sassolas
JGJ. J. Grob
J. J. Grob
Background: The treatment of stage I Merkel cell carcinoma (MCC) usually includes wide local excision (WLE) combined with irradiation of the tumor bed (ITB). No randomized study has ever been conducted in MCC. The purpose of this study was to assess the efficacy and safety of prophylactic adjuvant radiotherapy on the regional nodes. Patients and methods: In this randomized open controlled study, patients for a stage I MCC treated by WLE and ITB were randomly assigned to regional adjuvant radiotherapy versus observation. Overall survival (OS) and probability of regional recurrence (PRR) were primary end points. Progression-free survival (PFS) and tolerance of irradiation were secondary end points. Results: Eighty-three patients were included before premature interruption of the trial, due to a drop in the recruitment mainly due to the introduction of the sentinel node dissection in the management of MCC. No significant improvement in OS (P = 0.989) or PFS (P = 0.4) could be demonstrated after regional irradiation, which, however, significantly reduced the PRR (P = 0.007) with 16.7% regional recurrence rate in the observation arm versus 0% in the treatment arm. The treatment was well tolerated. Conclusion: The adjuvant regional irradiation significantly decreased the PRR in MCC, but benefit in survival could not be demonstrated.

4 May 2013 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
FJF. Julia
F. Julia
TPT. Petrella
T. Petrella
Marie BEYLOT-BARRYMarie BEYLOT-BARRY
Marie BEYLOT-BARRY
MBM. Bagot
M. Bagot
DLD. Lipsker
D. Lipsker
SDS. Dalle
S. Dalle

10 November 2014 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
MJMarie Jachiet
Marie Jachiet
BFBéatrice Flageul
Béatrice Flageul
ADAlban Deroux
Alban Deroux
AQAlain Le Quellec
Alain Le Quellec
FMFrançois Maurier
François Maurier
FGfor the French Vasculitis Study Group
for the French Vasculitis Study Group
Objective: Hypocomplementemic urticarial vasculitis (HUV) is an uncommon vasculitis of unknown etiology that is rarely described in the literature. We undertook this study to analyze the clinical spectrum and the therapeutic management of patients with HUV.Methods: We conducted a French nationwide retrospective study that included 57 patients with chronic urticaria, histologic leukocytoclastic vasculitis, and hypocomplementemia. We assessed clinical and laboratory data and evaluated the patients' cutaneous and immunologic responses to therapy. We evaluated treatment efficacy by measuring the time to treatment failure.Results: Urticarial lesions were typically more pruritic than painful and were associated with angioedema in 51% of patients, purpura in 35%, and livedo reticularis in 14%. Extracutaneous manifestations included constitutional symptoms (in 56% of patients) as well as musculoskeletal involvement (in 82%), ocular involvement (in 56%), pulmonary involvement (in 19%), gastrointestinal involvement (in 18%), and kidney involvement (in 14%). Patients with HUV typically presented with low C1q levels and normal C1 inhibitor levels, in association with anti‐C1q antibodies in 55% of patients. Hydroxychloroquine or colchicine seemed to be as effective as corticosteroids as first‐line therapy. In patients with relapsing and/or refractory disease, rates of cutaneous and immunologic response to therapy seemed to be higher with conventional immunosuppressive agents, in particular, azathioprine, mycophenolate mofetil, or cyclophosphamide, while a rituximab‐based regimen tended to have higher efficacy. Finally, a cutaneous response to therapy was strongly associated with an immunologic response to therapy.Conclusion: HUV represents an uncommon systemic and relapsing vasculitis with various manifestations, mainly, musculoskeletal and ocular involvement associated with anti‐C1q antibodies, which were found in approximately half of the patients. The best strategy for treating HUV has yet to be defined.

22 June 2009 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
SDS. Dalle
S. Dalle
Marie BEYLOT-BARRYMarie BEYLOT-BARRY
Marie BEYLOT-BARRY
MBM. Bagot
M. Bagot
DLD. Lipsker
D. Lipsker
LMLaurent Machet
Laurent Machet
TPT. Petrella
T. Petrella

1 May 2004 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
LMLaurent Machet
Laurent Machet
CCC. Couhe
C. Couhe
APA. Perrinaud
A. Perrinaud
CHC. Hoarau
C. Hoarau
GLG. Lorette
G. Lorette
LVL. Vaillant
L. Vaillant